雅虎香港 搜尋

搜尋結果

  1. 2018年3月8日 · Vaxigrip Tetra is well tolerated, has aroused no safety concerns, and is recommended for the active immunization of individuals aged ≥6 months. In addition, preliminary data confirm its immunogenicity and safety even in children aged 6-35 months and its immunogenicity in older subjects (aged 66-80 years).

  2. 2018年3月8日 · Vaccines (Basel). 2018 Mar; 6 (1): 14. Published online 2018 Mar 8. doi: 10.3390/vaccines6010014. PMCID: PMC5874655. PMID: 29518013. Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.

    • Emanuele Montomoli, Alessandro Torelli, Ilaria Manini, Elena Gianchecchi
    • 10.3390/vaccines6010014
    • 2018
    • Vaccines (Basel). 2018 Mar; 6(1): 14.
  3. Attachment 1: Product AusPAR - Vaxigrip Tetra - Inactivated quadrivalent influenza vaccine (split virion) - Sanofi-Aventis Australia Pty Ltd - PM-2018-00583-1-2 FINAL 19 December 2019. This

  4. VAXIGRIP TETRA is indicated for the prevention of influenza disease caused by the two influenza. virus subtypes and the two influenza B virus types contained in the vaccine for: active immunisation of adults, including pregnant women, and children from 6 months of age. and older,

  5. 1 天前 · Vaxigrip Tetra is a vaccine. This vaccine helps to protect you or your child against influenza (flu). Vaxigrip Tetra is used to prevent flu in persons of 6 months of age and older. If you are...

  6. AusPAR - Vaxigrip Tetra - Inactivated quadrivalent influenza vaccine (split virion) - Sanofi-Aventis Australia Pty Ltd - PM-2018-00583-1-2 FINAL 19 December 2019 Page 4 of 30